Aortic Valve Disease and Heart Failure with Mildly Reduced Ejection Fraction: New Insights and Pending Questions

医学 射血分数 心脏病学 心力衰竭 内科学 疾病
作者
Gaspard Suc,Bernard Iung
出处
期刊:European Journal of Heart Failure [Oxford University Press]
卷期号:26 (8): 1847-1849
标识
DOI:10.1002/ejhf.3360
摘要

This article refers to 'Prevalence and prognosis of aortic valve diseases in patients hospitalized with heart failure with mildly reduced ejection fraction' by T. Schupp et al., published in this issue on pages xxx. Although left ventricular (LV) remodelling differs between the different types of valvular diseases, consequences on LV ejection fraction (LVEF) represent a major prognostic factor, and therefore a potent driver for intervention, particularly in asymptomatic patients.1, 2 Impairment of LVEF is also a strong determinant of the occurrence of symptoms of heart failure in valvular disease. In patients with severe aortic stenosis (AS), it is well known for decades that the association of heart failure with LVEF <50% is associated with a particularly poor outcome with a life expectancy (50% mortality) as short as 1 year.3, 4 The strongest evidence concerning the prognostic impact of LV dysfunction was shown for LVEF <40%. In one of the largest series including 1402 patients who underwent surgical aortic valve replacement (SAVR), the 416 patients with LVEF ≤40% presented also with more frequent comorbidities, particularly ischaemic heart disease, than those with LVEF >40%.5 This raises the question of the respective contributions of LV remodeling in response to pressure overload due to AS and other determinants of LV systolic dysfunction. In patients with severe chronic aortic regurgitation (AR), the response to volume overload leads to LV enlargement resulting at a later stage in an impairment of LVEF. The relationship between decreasing LVEF and gradual overmortality has also been clearly demonstrated.6 In recent years, multimodality imaging has led to better insights in LV remodelling in patients with valvular disease. Echocardiographic analysis of LV strain is more sensitive than LVEF to detect subtle impairment of LV function which has a prognostic value.7 Tissue characterization using cardiac magnetic resonance enable in-depth analysis of LV remodelling. In patients with AS, the type and amount of fibrosis have been identified as prognostic factors of incremental value, particularly regarding irreversible replacement fibrosis, which differs from diffuse interstitial fibrosis which is reversible.8 The prognostic value of myocardial fibrosis has also been shown in chronic AR. Multimodality imaging is also useful to identify other causes of LV dysfunction, such as fibrotic sequalae of ischaemic heart disease or transthyretin amyloidosis.7 In this issue of the Journal, Schupp et al.9 report a retrospective single-centre analysis of 2106 patients hospitalized for heart failure with mildly reduced ejection fraction (HFmrEF, defined as a LVEF 41–49%). The originality of this paper is to focus on the recently characterized entity of HFmrEF in a large population, while older studies on LV dysfunction in patients with valvular disease were based on smaller populations and concerned patients with a wider range of impaired LVEF. Another strength is the analysis of the whole spectrum of aortic valve disease, from mild to severe. In the study by Schupp et al., patients were stratified according to the presence and severity of aortic valve disease. Older age and more frequent comorbidities in patients who had aortic valve disease in this cohort reflect the contemporary epidemiology of valvular heart disease. AS was moderate or severe in 9.8% of cases (moderate in 6.1% and severe in 3.7%) and AR was moderate or severe in 3.9% of cases (moderate in 3.7% and severe in 0.2%). Increasing severity of AS was associated with older age, more frequent comorbidities, and more severe symptoms. During a median follow-up of 30 months, there was a gradual increase in mortality and heart failure hospitalization with increasing severity of AS and AR. In a multivariable analysis adjusting for comorbidities, mild, moderate, and severe AS were all associated with higher all-cause mortality. Conversely, moderate or severe AR was not associated with increased mortality. The findings of Schupp et al. represent an important contribution to the risk stratification of HFmrEF according to aortic valvular heart disease. They also raise questions and point out the need for improving our knowledge of interactions between valvular disease and LV function to optimize patient management. The strong association between AS of any severity and all-cause mortality should not lead to overinterpretation in terms of the causal role of AS. There is a consensus on the need for intervention in patients with heart failure when AS is severe. In patients with moderate AS, recent data suggest a possible benefit in selected patients with heart failure.10 Conversely, mild AS does not have significant haemodynamic consequences. Mild AS therefore appears to be more a marker of risk rather than a cause of overmortality per se. This finding is consistent with the relationship between aortic sclerosis and increased cardiovascular mortality.11 This association makes sense since there are common pathways in the pathophysiology of AS and atherosclerosis.12 However, increased risk associated with mild AS was more pronounced in the study by Schupp et al. for all-cause mortality than for hospitalization for heart failure, thereby suggesting that the relationship between mild AS and poor outcome is mediated not only by cardiovascular diseases. Although the relationship between mild AS and overmortality remained significant in multivariable analysis in the paper by Schupp et al., the influence of unmeasured non-cardiac confounding factors cannot be excluded. At the other end of the spectrum of AS, an unexpected finding of the study by Schupp et al. is the low rate of interventions in patients with HFmrEF and severe AS. Transcatheter aortic valve implantation (TAVI) was performed in 27.5% of patients with severe AS and SAVR in 8.8%. Almost two thirds of patients were not treated for severe AS although their presentation corresponds to a class I indication in European as well as in American guidelines.1, 2 Although the appropriateness of the decision to intervene cannot be assessed for each patient in the present study, these findings raise concern regarding a possible underuse of interventions on the aortic valve. Comorbidities may be a valid reason to deny surgery but were less frequently mentioned than patient refusal. This is surprising since patient reluctance to interventions now occurs less frequently with the wide availability of TAVI. It should be stressed that failure to intervene in severe AS has been described as a major risk factor for short-term mortality.13 The findings of the study by Schupp et al. support close follow-up, aggressive management of cardiovascular risk factors and guideline-directed medical therapy of HFmrEF in patients with mild or moderate AS, but also increased awareness toward indications of TAVI or SAVR in those with severe AS. At the present time, intervention on the aortic valve should not be proposed in patients with moderate AS in the absence of randomized trials, such as the ongoing TAVR UNLOAD (Transcatheter Aortic Valve Replacement to Unload the Left Ventricle in Patients With Advanced Heart Failure, NCT02661451). Conversely to AS, the relationship between AR and increased mortality was no longer significant in multivariable analysis. This should be interpreted in the light of the very low percentage of severe AR (0.2%) and it is of importance to recall that LVEF <50% is a class I indication for intervention in patients with severe AR.1, 2 Despite higher operative mortality, SAVR is associated with improved survival in patients with severe AR and LV dysfunction as compared with medical therapy, so that those patients should not be denied surgery.14 On the other hand, patients with mild or moderate AR deserve medical therapy (Figure 1). In conclusion, the study by Schupp et al. provides valuable insights into the risk stratification of patients with HFmrEF in the context of aortic valve disease. Their findings have the merit to draw attention on the particularly poor outcome of patients with AS and heart failure, even when LVEF is moderately impaired, and on the need for reinforcing guideline implementation in patients with severe AS. Further research is needed in patients with mild and moderate aortic valve disease to elucidate the underlying mechanisms of the association between valvular disease with few of no haemodynamic consequences and impaired outcome in patients with HFmrEF. Any overinterpretation of this association is necessary to avoid unjustified indications of intervention on the aortic valve. Conflict of interest: none declared.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
Lwssss发布了新的文献求助10
2秒前
1001发布了新的文献求助10
3秒前
abcd完成签到 ,获得积分10
3秒前
4秒前
Agoni发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
喵不吃鱼发布了新的文献求助10
6秒前
斤斤计较完成签到,获得积分20
6秒前
GIN的应助被noliey采纳,获得30
7秒前
1liuxiaog发布了新的文献求助10
8秒前
伤心猪大肠完成签到,获得积分10
8秒前
9秒前
9秒前
WD发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
Akim的应助被研友_kngjrL采纳,获得30
11秒前
bruce完成签到,获得积分10
11秒前
11秒前
勤恳镜子完成签到,获得积分10
12秒前
12秒前
不仅要发文章还有发财完成签到,获得积分10
12秒前
icccce完成签到,获得积分10
13秒前
zZZZ发布了新的文献求助10
13秒前
ddifang完成签到,获得积分20
13秒前
14秒前
Frank发布了新的文献求助10
14秒前
xingzhou发布了新的文献求助10
14秒前
lisansui521发布了新的文献求助10
15秒前
田様的应助被1liuxiaog采纳,获得10
15秒前
宇轩完成签到,获得积分10
15秒前
小白发布了新的文献求助10
15秒前
科目三的应助被靓丽的紫菱采纳,获得10
16秒前
16秒前
17秒前
高高发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928